Dedicated to multi-modality treatment of benign skull base tumors, Adaptive Hybrid Surgery helps to balance surgical risk with radiosurgical toxicity.
Aggressive surgical interventions aiming at gross total resection have long been the standard treatment for most benign brain tumors, despite associated complications including disabling morbidity. Today, more than half of all cranial benign growths are alleviated surgically using less aggressive approaches, requiring an adjuvant treatment, such as stereotactic radiosurgery, to maximize tumor control. There is, however, no general consensus in determining when a resection is sufficient and when follow-up radiosurgery treatment is safe. Aiming to achieve the maximum safe surgical resection without any guidance may cause morbidity and irreversible neurological damage. Adaptive Hybrid Surgery Analysis automatically calculates and visualizes SRS/RT treatment plans, offering the possibility to combine the benefits of surgery with the benefits of radiosurgery.
• On-the-fly feasibility analysis of adjuvant radiosurgery
• Complete treatment workflow from planning to intraoperative decision-making
• Support of interdisciplinary collaboration
• Upfront integration of radiosurgery to avoid late referrals and potentially restricted treatment options
Brainlab offers a complete set of automated tools that enable neurosurgeons to continuously evaluate the feasibility of complementary radiosurgery at any time while planning and performing a surgical resection. Rather than relying on intuition, this helps establish the ideal crossover point between the two treatment techniques, balancing surgical risk and radiation toxicity when determining the extent of subtotal resection.
• Assists in establishing the ideal crossover point between surgery and radiosurgery
• Holistic treatment decisions consider amount of risk to the patient
• Opens new horizons for preservation of function without compromising tumor control rates
First, the surgeon defines what is expected to be reasonable residual tumor based on available preoperative images. Fully automated treatment plan calculation enables fast simulation and optimization of the desired residual tumor to fulfill both surgical and radiosurgical constraints. Therefore, tumor board discussions can be enriched with meaningful information above and beyond the available preoperative images.
• Automatic segmentation of critical structures
• Dose prescriptions and limits established by expert group
• Automatic calculation of single fraction SRS, hypo-fractionated SRS and conventionally fractioned SRT treatment plans
• Definition of a ‘planned cut’ object that can be exported to cranial navigation
An extension of the image guided feature set allows evaluation of all opportunities throughout surgery. Intraoperative, on-the-fly update of radiosurgery feasibility is possible when the system knows the residual tumors’ properties. Elements Intraoperative Structure Update¹ calculates a residual tumor object based on points acquired inside the resection cavity and automatically transfers this information to Adaptive Hybrid Surgery Analysis.
• Intraoperative point collection with navigated instruments
• Full integration with Brainlab cranial navigation software
• Automatic export of updated tumor information to Elements Adaptive Hybrid Surgery Analysis
Assess all required information instantaneously and simultaneously. An intuitive traffic light display provides comprehensive information about tumor coverage and critical dose constraints for all three calculated treatment plans. Quick plan assessment for non-radiation oncologists is facilitated, while additional information can be accessed for advanced plan assessment.
• Intuitive visualization for result interpretation by neurosurgeons
• Detailed dose information for optional radiation oncologists consultation
• Optimized for Curve™ Dual Display and Brainlab planning stations
• Visualization of complete strategy for treatment discussion with patient